Clinical Trial

Rapamycin - Effects on Alzheimer's and Cognitive Health

Name: Rapamycin - Effects on Alzheimer's and Cognitive Health — clinical trial record (NCT04629495)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REACH

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).

Trial Details

NCT Number	NCT04629495
Lead Sponsor	The University of Texas Health Science Center at San Antonio Collaborators: Alzheimer's Association
Conditions	Mild Cognitive Impairment, Alzheimer Disease
Enrollment	40 participants
Start Date	2021-08-11
Primary Completion	2026-03-05 (estimated)
Study Completion	2027-03-05 (estimated)
Updated on ClinicalTrials.gov	2026-06-09